Safety and rational use of the triptans

Medical Clinics of North America

Volumn 85, Issue 4, 2001, Pages 959-970

  Tepper, Stewart J ^b  

^a NEW ENGLAND CENTER FOR HEADACHE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT; SEROTONIN AGONIST;

CARDIOVASCULAR DISEASE; DRUG SAFETY; DRUG USE; HUMAN; MIGRAINE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0034922939     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(05)70353-9     Document Type: Article

References (71)

1. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine
2. Amerge, prescribing information
3. Transcranial magnetic stimulation confirms hyperexcitability of occipital cortex in migraine
4. Abnormal brain and muscle energy metabolism shown by 31P magnetic resonance spectroscopy in patients affected by migraine with aura
5. Magnetoencephalographic studies in migraine
6. Serotonin syndrome
7. Effects of the anti-migraine drug sumatriptan on muscle energy metabolism: Relationship to side effects
8. The pharmacokinetics of frovatriptan (VML 251/SB 209509), a potent selective 5-HT 1B/1D agonist, following single dose administration by oral and intravenous routes to healthy male and female volunteers
9. The pharmacokinetics and tolerability of almotriptan in renal impairment
10. Pharmacokinetic and metabolic data on almotriptan, a new antimigraine drug
11. Efficacy of subcutaneous sumatriptan in repeated episodes of migraine
12. Treatment of acute migraine with subcutaneous sumatriptan
13. Effect of early intervention with sumatriptan on migraine pain: Retrospective analyses of data from three clinical trials
14. Pharmacokinetic and food interaction of MK-462 in healthy males
15. Naratripan: Biological profile in animal models relevant to migraine
16. Multiple attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine
17. Central sites of action are important for the antimigraine efficacy of triptan-5-HT 1B/1D agonists
18. A placebo-controlled study of intranasal sumatripan for the acute treatment of migraine
19. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan
20. Oral naratriptan tablets (2.5-10 mg) exhibit dose proportional pharmacokinetics
21. 1B/1D agonists in migraine: Comparative pharmacology and its therapeutic implications
22. Practicability and acceptance of subcutaneous self-administration of the selective serotonin agonist sumatriptan
23. Single and multiple-dose pharmacokinetic and tolerability of rizatripan, a novel 5-HT 1D/1B agonist for migraine
24. Analysis of cerebral responses in flicker in patients complaining of episodic headache
25. In vitro profile of eletriptan, a new '5-HT 1D like' receptor partial agonist
26. Pathophysiology and migraine - New insights
27. Oral naratriptan tablets (2.5-10 mg) exhibit dose proportional pharmacokinetics
28. Naratriptan is effective and well tolerated in the acute treatment of migraine: Results of a double-blind, placebo-controlled, parallel group study
29. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks
30. Rizatriptan 5 mg versus sumatriptan 50 mg in the acute treatment of migraine
31. Treatment of mild headache in disabled migraine sufferers: Results of the Spectrum Study
32. Stratified care vs step care strategies for migraine. The Disability in Strategies of Care (DISC) Study
33. Differential distribution of 5-HT1D- and 5-HT1B-immunoreactivity within the human trigeminocerebrovascular system: Implications for the discovery of new anti-migraine drugs
34. Coronary side-effect potential of current and prospective antimigraine drugs
35. Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation
36. Preclinical and clinical pharmacology of zolmitriptan (311C90): A novel antimigraine agent
37. Long term efficacy and tolerability of almotriptan: Results of a 1-year open study on almotriptan
38. Naratriptan is effective and well tolerated in the acute treatment of migraine: Results of a double-blind, placebo-controlled, crossover study
39. Serotonin syndrome complicating migraine pharmacotherapy
40. Maxalt prescribing information
41. The pharmacokinetic profile of eletriptan
42. D-like" receptor partial agonist
43. The safety, tolerability and pharmacokinetics of oral eletriptan (UK-116,044), a potent and selective '5-HT 1D-like' receptor agonist
44. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses
45. Prospective large-scale study of the tolerability of subcutaneous sumatriptan for the acute treatment of migraine
46. Sumatriptan nasal spray - A dose-ranging study in the acute treatment of migraine
47. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: Defining the optimum doses of oral sumatriptan
48. The clinical profile of sumatriptan: Efficacy in migraine
49. Migraine polypharmacy and the tolerability of sumatriptan: A large-scale, prospective study
50. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine: A multicenter, double-blind, placebo-controlled, dose range-finding study
51. The long term tolerability, safety and efficacy of sumatriptan 20 mg nasal spray in the acute treatment of migraine
52. Sumatriptan nasal spray for the acute treatment of migraine: Results of two clinical studies
53. A preliminary study of VML 251 (SB209509), a novel 5HT 1B/1D agonist for the treatment of acute migraine
54. Intranasal sumatriptan for the acute treatment of migraine
55. The novel antimigraine drug 311C90 has no clinically significant interactions with likely concomitant medications
56. The pharmacokinetics and safety of eletriptan in volunteers and migraineurs
57. Low migraine headache recurrence with naratriptan: Clinical parameters related to recurrence
58. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine
59. Treatment of migraine attacks with sumatriptan
60. Long term experience with sumatriptan in the treatment of migraine
61. Rizatriptan (Maxalt) for the acute treatment of migraine and migraine recurrence: A placebo-controlled, outpatient study
62. A long-term study to maximise migraine relief with zolmitriptan
63. Oral rizatriptan versus oral sumatriptan: A direct comparative study in the acute treatment of migraine
64. Overlapping substate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
65. Brain stem activation in spontaneous human migraine attacks
66. Serotonin syndrome: Case report and review of the literature
67. The concept of migraine as a state of central neuronal hyperexcitability
68. Tolerability and appropriate use of sumatriptan: Clinical trials and post marketing experience
69. The contributions of P-glycoprotein to pharmacokinetic drug-drug interactions
70. Zomig prescribing information